BT#141

BT#141 (also known as BT-141) is a boron-based small molecule peptidomimetic analog of the adenoviral protein E4orf1 (early gene 4, open reading frame-1). Developed by researchers at Texas Tech University, BT#141 is designed to improve glycemic control and insulin sensitivity. It mimics the action of E4orf1 by binding to the PDZ domain of Drosophila discs-large homolog 1 (Dlg1), which triggers the activation of the downstream Ras-mediated phosphatidylinositol 3-kinase (PI3K)/Akt signaling pathway. This insulin-independent pathway promotes the translocation of glucose transporter 4 (GLUT4) to the cell membrane, enhancing cellular glucose uptake in adipocytes and skeletal muscle. BT#141 is being investigated as a potential therapeutic agent for type 2 diabetes, insulin resistance, and obesity-related metabolic disorders.